ARK Genomic Revolution ETF
ARKG
321 hedge funds and large institutions have $523M invested in ARK Genomic Revolution ETF in 2022 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 62 increasing their positions, 131 reducing their positions, and 38 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
39% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 38
3% more funds holding
Funds holding: 312 → 321 (+9)
0% more call options, than puts
Call options by funds: $63M | Put options by funds: $62.9M
2.4% less ownership
Funds ownership: 29.82% → 27.42% (-2.4%)
27% less capital invested
Capital invested by funds: $715M → $523M (-$192M)
53% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 131
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$37.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$13.4M |
| 3 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$3.88M |
| 4 |
Jane Street
New York
|
+$3.81M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$49M |
| 2 |
Morgan Stanley
New York
|
-$43.5M |
| 3 |
Goldman Sachs
New York
|
-$21.4M |
| 4 |
Rockefeller Capital Management
New York
|
-$10.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.11M |
ARKG Hedge Fund Activity: Q4 2022 in Review
321 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2022, worth a combined $523M — down 27% from $715M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ARKG positions and 38 closed out — a net gain of 15 holders — while 62 added to existing stakes and 131 trimmed.
The largest buyer was Wells Fargo, adding an estimated $37.6M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $49M.
- 321 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2022, up from 312 in Q3 2022.
- Funds reported $523M of ARK Genomic Revolution ETF stock for Q4 2022, down 27% quarter-over-quarter.
- 53 funds opened new ARK Genomic Revolution ETF positions in Q4 2022 and 38 closed out, a net change of +15 holders.
- The largest ARK Genomic Revolution ETF buyer in Q4 2022 was Wells Fargo, an estimated $37.6M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2022 was BNP Paribas Financial Markets, an estimated $49M sold.
Based on aggregated 13F filings for Q4 2022.